Medicine & pharma · Pipeline & development
Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR; - 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage...
Original source
Read the source — prnewswire.com ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.